A股異動 | 歐普康視(300595.SZ)漲超5% 擬3226.53萬元增資昆明視康獲51%股權
格隆匯7月28日丨歐普康視(300595.SZ)午後漲幅擴大,現報64.49元,漲5.62%,暫成交3.5億元,最新總市值391億元。歐普康視今日午間公佈,公司全資子公司歐普投資擬以自有資金人民幣3226.53萬元以增資擴股的方式投資於昆明視康。該次投資完成後,歐普投資將持有昆明視康51%的股權。昆明視康主要業務有眼科診所服務、健康諮詢、乾眼專科、小兒眼科、屈光矯正、驗光配鏡、醫療器械及光學儀器的銷售等。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.